Short Interest in IsoRay, Inc. (ISR) Drops By 6.8%

Share on StockTwits

IsoRay, Inc. (NYSEAMERICAN:ISR) was the target of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totalling 771,025 shares, a decrease of 6.8% from the April 15th total of 827,421 shares. Currently, 1.2% of the shares of the stock are short sold. Based on an average daily volume of 178,512 shares, the days-to-cover ratio is currently 4.3 days.

Shares of NYSEAMERICAN:ISR opened at $0.44 on Wednesday. IsoRay has a fifty-two week low of $0.27 and a fifty-two week high of $1.22.

IsoRay (NYSEAMERICAN:ISR) last issued its earnings results on Thursday, May 9th. The healthcare company reported ($0.02) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.02). The company had revenue of $1.92 million for the quarter, compared to the consensus estimate of $1.92 million.

A number of equities analysts have weighed in on ISR shares. HC Wainwright reiterated a “buy” rating and issued a $0.70 price target on shares of IsoRay in a research report on Monday, January 28th. Zacks Investment Research upgraded shares of IsoRay from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research report on Friday, May 17th.

Large investors have recently modified their holdings of the stock. Highland Private Wealth Management bought a new position in shares of IsoRay during the fourth quarter worth $39,000. Vanguard Group Inc boosted its position in shares of IsoRay by 24.7% during the third quarter. Vanguard Group Inc now owns 1,857,268 shares of the healthcare company’s stock worth $964,000 after acquiring an additional 367,324 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of IsoRay by 24.7% during the third quarter. Vanguard Group Inc. now owns 1,857,268 shares of the healthcare company’s stock worth $964,000 after acquiring an additional 367,324 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4348765/short-interest-in-isoray-inc-isr-drops-by-6-8.html.

IsoRay Company Profile

IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Featured Story: Why do company’s buyback their stock?

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Buying: Century Bancorp, Inc.  Major Shareholder Purchases 200 Shares of Stock
Insider Buying: Century Bancorp, Inc. Major Shareholder Purchases 200 Shares of Stock
salesforce.com, inc.  Director John Victor Roos Sells 113 Shares
salesforce.com, inc. Director John Victor Roos Sells 113 Shares
Century Bancorp, Inc.  Major Shareholder Acquires $17,300.00 in Stock
Century Bancorp, Inc. Major Shareholder Acquires $17,300.00 in Stock
Samuel Gazal Buys 1,750,000 Shares of K2 Energy Limited  Stock
Samuel Gazal Buys 1,750,000 Shares of K2 Energy Limited Stock
Gordon R. Bernard Sells 2,050 Shares of Cumberland Pharmaceuticals, Inc.  Stock
Gordon R. Bernard Sells 2,050 Shares of Cumberland Pharmaceuticals, Inc. Stock
Cumberland Pharmaceuticals, Inc.  Director Gordon R. Bernard Sells 1,859 Shares
Cumberland Pharmaceuticals, Inc. Director Gordon R. Bernard Sells 1,859 Shares


© 2006-2019 Ticker Report